As a result, they’re more likely to develop X-linked conditions like Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy — the two most common types of the condition — if one of ...

MicroRNA-33a and microRNA-33b are encoded within the mammalian SREBF1 and SRBF2 genes, respectively, and both SREBF1 and ...

Duchenne and Becker muscular dystrophy, as well as some types of Emery-Dreifuss muscular dystrophies, arise as a result of mutations on one of the X chromosomes carried by the female parent.

Muscular dystrophy is the overarching name for a group of illnesses that progressively cause a reduction in muscle mass and weakness in the body. Each type of muscular dystrophy is a genetic condition ...

Becker muscular dystrophy causes long-term disability and is life-threatening because of its effects on the heart. No therapies are currently approved for Becker muscular dystrophy in the United ...

A father of two sons diagnosed with muscular dystrophy is organizing a cornhole tournament this weekend to raise money for ...

Becker Muscular Dystrophy, much like Duchenne Muscular Dystrophy, is a type of genetic disorder that causes progressive muscle weakness and degeneration over time, primarily in males.

The symptoms of Becker muscular dystrophy are similar to those of Duchenne muscular dystrophy. But Becker muscular dystrophy starts later -- around the teen years. It also develops much more slowly.

In addition to papers on Muscular dystrophies: causes and treatment, Scientific Reports welcomes all original research in the field of diseases. To browse our latest articles in diseases click here .

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the two most common forms of the disease, representing 80% of all cases of muscular dystrophy. Both diseases almost ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseasesCapricor remains on track for the ...

Edgewise Therapeutics, Inc.,, a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally administered first-in ...